We next tested whether combining CpG-Stat3 siRNA with CTLA4 or PD-1 inhibition would lead to superior antitumor effects relative to the single agents in the mouse B cell lymphoma. This evidence concerns the gene STAT3 and B-cell non-Hodgkin lymphoma.